New PSA Testing Guidelines in 2026: What Every Man Should Know

ExcelMale Consensus
The 2026 prostate cancer screening guidelines from the American Cancer Society, the European Association of Urology and the American Urological Association now support regular PSA testing adjusted to each man's risk. After 23 years of follow-up, the ERSPC trial prevented one prostate cancer death for every 456 men invited to screening (Roobol 2025). Get a baseline PSA by 50, or by 45 if you are Black or have a strong family history, and get one before you start TRT.

Key Takeaways
  • The American Cancer Society now recommends a PSA test every 2 years for average-risk men aged 50 to 69. It is the first ACS update since 2010.
  • Under the ACS guideline, Black men and men with a close relative diagnosed before 65 test every year starting at 45.
  • A PSA of 3.0 ng/mL or higher (age 69 and under) must be confirmed with a retest before anyone discusses biopsy.
  • A confirmed high PSA now leads to an MRI or a validated biomarker test first, before a biopsy decision.
  • The USPSTF still uses its 2018 advice. The UK will screen only BRCA2 carriers who also have a family history of cancer.
  • Men on TRT need a PSA before starting and again at 3 to 12 months, per the Endocrine Society.


Chart comparing 2026 PSA screening guidelines by start age, stop age and testing interval for ACS, AUA, EAU, USPSTF and UK


For 16 years, the American Cancer Society told men to talk PSA testing over with their doctor and decide for themselves. On November 12, 2026, it stopped hedging. The new guideline names specific ages and PSA cutoffs, and it lands six months after Cochrane reversed its own position on screening. PSA has been argued over in ExcelMale threads for as long as the forum has existed, so here is what each major guideline now says and what it means if you are on testosterone.

Why Did Prostate Cancer Screening Guidelines Change in 2026?​

The guidelines changed because the long-term screening trials finally ran long enough to show a clear drop in prostate cancer deaths. Short follow-up hid the benefit. Longer follow-up exposed it.

The European ERSPC trial followed more than 160,000 men. After a median of 23 years, prostate cancer deaths were 13% lower in the screened group (Roobol 2025).

At 23 years, ERSPC prevented one prostate cancer death for every 456 men invited to screening, down from 1,410 in its first report (Roobol 2025).

The Swedish Göteborg-1 trial found 29% fewer prostate cancer deaths after 22 years of PSA testing every second year (Frånlund 2022). The UK CAP trial, which offered men a single PSA test, showed a smaller reduction at 15 years (Martin 2024). One test is not a screening program.

In May 2026, Cochrane concluded for the first time that PSA screening likely reduces prostate cancer deaths, by about 2 per 1,000 men over 23 years (Franco 2026). Its 2006 and 2013 reviews had found no clear benefit. The trials did not change. The follow-up got longer.

What Is the Downside of PSA Screening?​

The main downside is overdiagnosis, which means finding cancers that would never have caused symptoms or death. Cochrane estimated about 36 extra cancers diagnosed per 1,000 men screened for every 1 to 2 deaths prevented (Franco 2026). That cost explains why the 2026 guidelines add confirmation and imaging steps before biopsy instead of dropping screening.

What Does the New American Cancer Society PSA Guideline Recommend?​

The ACS now recommends a PSA test every 2 years for average-risk men aged 50 to 69, a grade B recommendation (Hoffman 2026). Before this update, the ACS did not recommend any specific screening schedule. Its 2010 guidance asked men to make an informed decision with their doctor.

Who Should Start PSA Screening at 45?​

Black men and men with a strong family history should start at 45 and test every year under the ACS guideline (Hoffman 2026). Black men test yearly from 45 to 69. Men with a first-degree relative (father or brother) diagnosed before 65, or several such relatives, also test yearly from 45. One relative diagnosed at 65 or older moves you to every 2 years from 45.

Two limits are worth knowing. The guideline does not cover inherited syndromes such as BRCA2, so carriers need genetics-specific advice. The advice for Black men also rests on modeling, and the ACS rates the certainty of evidence for starting at 45 as low.

When Should Men Stop PSA Screening?​

The ACS calls screening at 70 to 74 an individual decision (grade C) and recommends against it at 75 or older, or with a life expectancy under 10 years (grade D) (Hoffman 2026). The digital rectal exam is no longer recommended as the main screening test (grade D).

What PSA Level Counts as Abnormal in 2026?​

Under the ACS guideline, a PSA of 3.0 ng/mL or higher is abnormal up to age 69, and 6.5 ng/mL or higher is abnormal at 70 to 74 (Hoffman 2026). An abnormal result must be confirmed with a repeat test 2 weeks to 3 months later. A confirmed high PSA leads to an MRI, a validated biomarker test, or both, before anyone decides on biopsy.

The retest rule is the part men should remember. One high reading after recent ejaculation or a prostate infection should not put you on a biopsy table.

How Do the AUA, EAU, NCCN, USPSTF and UK PSA Screening Guidelines Compare?​

Most major groups now favor regular, risk-adjusted PSA screening, while the USPSTF and the UK National Screening Committee remain the conservative outliers. The table below lines them up.

GuidelineAverage-risk startHigher-risk startIntervalStopNext step after high PSA
ACS 20265045 (Black men, family history)2 years; yearly if higher risk70 to 74 individual; not at 75+Retest; MRI and/or biomarker if 3.0+ confirmed
AUA/SUO 2023 (amended 2026)Baseline 45 to 50; regular 50 to 6940 to 452 to 4 yearsIndividualizedRepeat PSA; updated biopsy sections
EAU 20265045 (African descent, family history before 60); 40 (BRCA2)2 years if PSA above 1 at 40 or 2 at 60; up to 8 if lowerBy life expectancy and healthRepeat if 3 to 10; MRI, risk calculator or biomarker if 3 to 20
NCCNSimilar to AUASimilar to AUA2 to 4 years, set by baseline PSAIndividualizedSimilar to AUA
USPSTF 201855 to 69, individual decisionNo separate adviceNot specifiedNot recommended at 70+Not specified
UK NSC 2026No population screening45 to 61, BRCA2 plus family history only2 years61Not specified

What Does the AUA Guideline Say?​

The AUA and Society of Urologic Oncology use PSA as the first screening test and recommend repeating a newly elevated PSA (Wei 2023). A baseline PSA may be offered at 45 to 50. Men with Black ancestry, inherited mutations or a family history can start at 40 to 45, and men aged 50 to 69 are screened every 2 to 4 years. The February 2026 amendment rewrote the biopsy sections and left the screening ages unchanged. NCCN guidance sits close to the AUA and uses the baseline PSA level to set the interval.

What Does the EAU Guideline Say?​

The EAU 2026 guideline starts screening at 50, at 45 for men of African descent or with a family history of prostate cancer before 60, and at 40 for BRCA2 carriers (EAU 2026). The interval depends on your baseline. A PSA above 1 ng/mL at 40, or above 2 ng/mL at 60, means retesting every 2 years. Men below those levels can wait up to 8 years.

New this year, a PSA of 3 to 10 is repeated before any workup. For PSA 3 to 20, the biopsy decision uses an MRI, a calibrated risk calculator or an extra biomarker. The EAU also says no man should get a PSA test without first being counselled on risks and benefits, and men without symptoms should not routinely get a rectal exam.

What Do the USPSTF and UK Recommend?​

The U.S. Preventive Services Task Force still uses its 2018 recommendation: men aged 55 to 69 make an individual decision with a clinician, and routine screening is not recommended at 70 and older (Grossman 2018). An update is in progress, and its review plan includes MRI and risk calculators before biopsy. No draft had been released as of November 2026.

In May 2026, the UK National Screening Committee recommended screening only for men aged 45 to 61 who carry a confirmed BRCA2 variant and have a family history of breast, ovarian, pancreatic or prostate cancer, with a PSA test every 2 years. The government accepted it, and rollout in England is expected in 2027. Screening for other high-risk groups, including Black men, was rejected.

How Does an MRI Before Biopsy Change PSA Screening?​

An MRI after a confirmed high PSA cuts unnecessary biopsies while keeping the same PSA threshold. CISNET modeling summarized with the ACS update found that keeping the 3.0 ng/mL cutoff and adding MRI reduced biopsies by 30% to 34% and overdiagnoses by 8% to 14% (Hoffman 2026).

A Dutch microsimulation reached a similar figure: 30% of men with a positive PSA could avoid biopsy when MRI came first (Getaneh 2021).

The old pathway sent a man from one high PSA straight to a 12-core biopsy. That pathway produced most of the harm critics blamed on the PSA test itself. Biomarkers add another filter. In one ExcelMale thread on a PSA of 5.3, a member on TRT used a SelectMDX urine test, got a negative result, and continued treatment with his urologist's approval.

What Do the 2026 PSA Screening Guidelines Mean for Men on TRT?​

If you are on TRT, get a PSA before you start and again 3 to 12 months later, then follow the screening schedule for your age and risk. The 2018 Endocrine Society guideline recommends urology referral when PSA rises more than 1.4 ng/mL within 12 months of starting testosterone, or when a confirmed PSA exceeds 4.0 ng/mL (Bhasin 2018). An abnormal prostate exam also warrants referral.

A modest rise in the first months is common. Hypogonadal men often run a low PSA, and testosterone brings it back toward the level expected for their age. This comes up constantly in the ExcelMale PSA levels on TRT survey, where members post first-year changes such as 0.9 to 1.8 ng/mL. Testosterone therapy has not been shown to cause prostate cancer, a point covered in our thread Does Testosterone Cause Prostate Cancer?.

How Should Men on TRT Handle a High PSA Result?​

Retest before acting, and control the variables that push PSA up. The new ACS window of 2 weeks to 3 months for confirmation works in your favor. Draw blood at the same point in your injection cycle, avoid ejaculation for 48 hours beforehand, and ask your doctor to rule out prostatitis.

In one ExcelMale thread, a member's PSA fell from 10.4 to 2.3 ng/mL after a course of antibiotics. In another, scrotal testosterone cream pushed a member's PSA above 4.0, and it returned to his usual 1.4 to 1.7 after he stopped the cream.

We have no trials testing the 2026 cutoffs in men on TRT. The 3.0 threshold was built on men making their own testosterone, so a TRT user near that line needs trend data more than a single number.

Frequently Asked Questions​

At what age should I get my first PSA test in 2026?​

Most guidelines put the first test at 50 for average-risk men and at 45 for Black men or men with a strong family history. The AUA allows a baseline at 45 to 50, and the EAU starts BRCA2 carriers at 40.

How often should I get a PSA test?​

Average-risk men aged 50 to 69 should test every 2 years under the ACS guideline. The AUA allows 2 to 4 years, and the EAU lets men with a low baseline PSA wait up to 8 years.

Is a PSA of 4.0 still the cutoff?​

No. The ACS now treats 3.0 ng/mL as abnormal up to age 69, and the EAU repeats any PSA of 3 to 10 before further workup. The Endocrine Society still uses 4.0 ng/mL as a referral trigger for men on TRT.

Does TRT cause prostate cancer?​

Current evidence does not show that TRT causes prostate cancer. It can raise PSA modestly, which is why the Endocrine Society calls for a PSA before treatment and again at 3 to 12 months (Bhasin 2018).

Do I still need a digital rectal exam?​

Not as your main screening test. The ACS gives the rectal exam a grade D as a primary screen, and the EAU advises against routine rectal exams in men without symptoms.

Related ExcelMale Forum Discussions​


Key References​

  1. Hoffman RM, Wolf AMD, Etzioni RD, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA Cancer J Clin. 2026. https://doi.org/10.3322/caac.70112
  2. Franco JVA, Hwang EC, Jung JH, et al. Prostate-specific antigen (PSA) test for prostate cancer screening. Cochrane Database Syst Rev. 2026;5:CD004720. https://doi.org/10.1002/14651858.CD004720.pub4
  3. Roobol MJ, et al. European Study of Prostate Cancer Screening: 23-Year Follow-up. N Engl J Med. 2025;393(17):1669-1680. https://doi.org/10.1056/NEJMoa2503223
  4. Frånlund M, Månsson M, Godtman RA, et al. Results from 22 years of followup in the Göteborg randomized population-based prostate cancer screening trial. J Urol. 2022;208(2):292-300. https://doi.org/10.1097/JU.0000000000002696
  5. Martin RM, Turner EL, Young GJ, et al. Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial. JAMA. 2024;331(17):1460-1470. https://doi.org/10.1001/jama.2024.4011
  6. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):46-53. https://doi.org/10.1097/JU.0000000000003491
  7. European Association of Urology. EAU Guidelines on Prostate Cancer, 2026 edition. https://uroweb.org/guidelines/prostate-cancer
  8. Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. https://doi.org/10.1001/jama.2018.3710
  9. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://doi.org/10.1210/jc.2018-00229
  10. Getaneh AM, Heijnsdijk EAM, de Koning HJ. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study. Sci Rep. 2021;11. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study - Scientific Reports

Conclusion​

One ERSPC finding gets little attention: the protection from screening starts to fade once men stop testing and is largely gone within nine years (Roobol 2025). That makes your stop age as important as your start age. If you are 69, healthy and expect to live another 15 years, the ACS window for an individual decision at 70 to 74 deserves a real conversation with your doctor.

If you are on TRT, you already get regular PSA draws. Make sure someone reads them as a trend. Compare your numbers with other members in the PSA levels on TRT survey, and read Does Testosterone Cause Prostate Cancer? before you let one high result end a protocol that works.

Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy or medical treatment.

By Nelson Vergel | B.S. Chemical Engineering, MBA | Founder, ExcelMale.com | 34+ years on TRT | NIH and FDA advisory panel service | Author: Testosterone: A Man's Guide, Beyond Testosterone, The hCG Advantage, and From Pills to Implants. Updated November 2026.

About ExcelMale:
ExcelMale.com is a men's health community founded by Nelson Vergel, with more than 43,000 members and over 20 years of archives covering testosterone replacement, hormone optimization, fertility, and men's sexual health. Join the conversation on the ExcelMale forum.
 
Last edited:
 

ExcelMale Newsletter Signup

Beyond Testosterone Podcast

Online statistics

Members online
7
Guests online
1,589
Total visitors
1,596

Latest posts

Back
Top